# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001764013-24-000114
Filing Date
2024-06-26
Accepted
2024-06-26 06:56:24
Documents
5
Period of Report
2024-08-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | imvt-20240331defproxy.htm | DEF 14A | 582077
2 | GRAPHIC | immunovantinc_vxprxyxgt20x.jpg | GRAPHIC | 497560
3 | GRAPHIC | immunovantinc_vxprxyxgt20xa.jpg | GRAPHIC | 240673
4 | GRAPHIC | table-capvsnl2024.jpg | GRAPHIC | 68137
5 | GRAPHIC | table-capvstsr2024.jpg | GRAPHIC | 73806
| Complete submission text file | 0001764013-24-000114.txt |  | 1795234

Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Filer) CIK: 0001764013 (see all company filings)

EIN.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
Type: DEF 14A | Act: 34 | File No.: 001-38906 | Film No.: 241070593
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)